Navigation Links
TorreyPines Therapeutics Appoints Evelyn Graham Chief Executive Officer and a Member of the Board of Directors
Date:11/12/2008

LA JOLLA, Calif., Nov. 12 /PRNewswire/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that the Board of Directors has appointed Evelyn Graham as the Company's Chief Executive Officer and as a member of the Company's Board of Directors. Ms. Graham had been serving as the Company's acting Chief Executive Officer since September 1, 2008.

"Ev has done an impressive job as acting CEO in managing the transition of our company and building a platform for the future," said Peter Davis, Chairman of the TorreyPines Board of Directors. "We are delighted that she has agreed to become CEO and a member of the Board at a time when TorreyPines is completing important clinical trials that hold promise for the company's future. With her considerable drug development experience as well as global senior management roles, she has the right mix of skills and experience to successfully lead the Company in meeting its strategic objectives."

"I am excited by this opportunity and look forward to continuing to work with TorreyPines' talented management team and dedicated employees," said Ms. Graham.

Ms. Graham joined TorreyPines in 2004 as Vice President, Development. She was then promoted to Vice President, Corporate Development in 2005, Chief Operating Officer in 2006 and acting Chief Executive Officer in September 2008. Prior to joining TorreyPines Ms. Graham was Executive Director, Development Operations at Purdue Pharma from 2000 to 2003. From 1998 to 2000, she was Senior Vice President of Business Development at Ingenix Pharmaceutical Services, a division of UHG, and served as Vice President of Clinical Operations at Worldwide Clinical Trials, prior to its acquisition by UHG. Previously, Ms. Graham held positions in oper
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. TorreyPines Therapeutics Reports Third Quarter 2008 Results and Recent Accomplishments
2. TorreyPines Therapeutics Sells Alzheimers Disease Genetics Program to Eisai
3. TorreyPines Therapeutics Begins Dosing in a Phase I Multiple Dose Clinical Trial of NGX426, Oral Prodrug of Tezampanel
4. TorreyPines Therapeutics Reports Successful End-of-Phase II Meeting With FDA for Tezampanel
5. TorreyPines Therapeutics Strategically Repositions as Development Company Focusing on Three Versatile Lead Compounds
6. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
7. TorreyPines Therapeutics to Present Tezampanel Phase IIb Clinical Data for Acute Migraine at 50th Annual Scientific Meeting of the American Headache Society
8. TorreyPines Therapeutics to Host First Quarter 2008 Results Conference Call and Webcast
9. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2007 Financial Results and Highlights
10. TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia
11. TorreyPines Therapeutics to Present at Susquehanna Financial Groups Second Annual SIGnificant Options in Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... INDIANAPOLIS , Oct. 30, 2014 A ... Battelle Technology Partnership Practice, takes an in-depth look at ... innovation outputs that have resulted over two different time ... also provides a view of future opportunities for investment ... Indiana report shows gains in innovation ...
(Date:10/27/2014)... (PRWEB) October 27, 2014 The ... by Type (High & Medium), Sub-type (Primary & ... Processing, Infrastructure & Transportation & Power Generation) - ... the GIS market with analysis and forecasting of ... Market Data Tables with 52 Figures spread through ...
(Date:10/27/2014)... BOSTON, MA (PRWEB) October 27, 2014 ... and profit. SoundConnect , an industry leading ... for its partners and agents to deliver cloud-based ... and accelerate growth opportunities. , With SoundConnect’s ... for every twenty-five video and/or web conferencing licenses ...
(Date:10/27/2014)... 27, 2014 Investor-Edge has initiated ... NBIX ), Insmed Inc. (NASDAQ: ... ), Dyax Corporation (NASDAQ: DYAX ), and ... companies can be accessed at: http://investor-edge.com/register . ... ended at 4,483.72, up 0.69%, the Dow Jones Industrial ...
Breaking Biology Technology:New report shows Indiana's gains in life sciences innovation capital outpace the nation 2New report shows Indiana's gains in life sciences innovation capital outpace the nation 3New report shows Indiana's gains in life sciences innovation capital outpace the nation 4New report shows Indiana's gains in life sciences innovation capital outpace the nation 5Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 2Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 3Gas Insulated Switchgear Market worth $21,951.9 Million by 2019 - New Report by MarketsandMarkets 4SoundConnect Unveils Q4 Partner Incentives 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5
... ARBOR, Mich.---A delicate balance of atomic forces can be ... size---an attribute that,s important for many nanotech applications but ... The same type of forces are at work ... inorganic supercluster structures in this research are in many ...
... announced today they have been named to the prestigious 30th ... entrepreneurial and fastest growing companies in America. The 2011 Inc. ... past three years.  HumanTouch is ranked 203 on this list. ... representatives of the Inc. 500 such as Zappos, Patagonia, Intuit ...
... 2011 Biotechnology leader Divine Skin Inc. (DSKX) posted ... quarter. The expanding innovator of personal care solutions credits ... sales, which are 79 percent ahead of the same ... has been keeping up with demand," said Divine Skin ...
Cached Biology Technology:Engineers discover nanoscale balancing act that mirrors forces at work in living systems 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 2Divine Skin Posts Record Q2 Revenue of $2.33 Million, up 79 Percent From 2010 3
(Date:10/29/2014)... research potential of the Barcode of Life Data ... Biodiversity Data Journal (BDJ) used ... imported these into a human-readable text developed in manuscript ... were used to study the species distributions of ten ... , BOLD is originally designed to support the generation ...
(Date:10/29/2014)... 29, 2014 – Ghrelin is a hormone released by ... Alcohol is commonly viewed as a psychoactive substance that ... highly caloric food. , This knowledge, combined with ... that ghrelin has the potential to stimulate alcohol craving. ... in humans and found that, as they had anticipated, ...
(Date:10/28/2014)... One of the tragic realities of cancer is ... highly toxic and their effectiveness varies unpredictably from ... is poised to change this reality by rapidly ... on an individual,s cancer before chemotherapy begins. , ... headed by Assistant Professor Melissa Skala has developed ...
Breaking Biology News(10 mins):Go straight and publish: From Barcode of Life Data Systems to scholarly publishing systems 2Ghrelin stimulates an appetite for drinking alcohol 2Improving breast cancer chemo by testing patient's tumors in a dish 2Improving breast cancer chemo by testing patient's tumors in a dish 3
... Zealand The first paternity study of southern right whales ... for males, scientists say, which is good news for the ... for local populations through in-breeding. Results of the study, ... and the New Zealand Department of Conservation, have just been ...
... from Ludwig-Maximilians-Universitt (LMU) in Munich have identified an enzyme ... essential for bacterial pathogenicity. Because it shows no similarity ... target for development of novel antimicrobial drugs. ... that these strains become pathogenic only when an enzyme ...
... at the University of Copenhagen have previously documented that ... Cyrtanthus akin to snowdrops and daffodils have ... are involved in depression. This research has now yielded ... of Health and Medical Sciences has recently shown how ...
Cached Biology News:First paternity study of southern right whales finds local fathers most successful 2First paternity study of southern right whales finds local fathers most successful 3South African daffodils may be a future cure for depression 2
... a manual heat sealer ideal for low to ... can seal a wide range of plates of ... heating element of the sealer is pre-set for ... seals when used in conjunction with ABgenes sealing ...
... controller is the successor to the original DS-U1. ... of the cameras in the Nikon DS camera ... interface. The DS-U2 transmits information at high speed, ... both hub and mass storage USB 2.0 interfaces. ...
...
This unique buffer provides a gentle method for removal of primary and secondary antibodies to allow several reprobings on the same membrane. Gentle buffer will not alter the antigen for subsequent i...
Biology Products: